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deterioration from hyponatremia for a variety of 
reasons, including being a woman2 and having a 
space-occupying lesion, vasogenic cerebral ede-
ma,3 and a hypoxic event.4 Hyponatremia can lead 
to cytotoxic cerebral edema, which expands brain 
tissue and can lead to herniation. No data were 
provided on either the composition of the intra-
venous fluid administered on admission or the 
serum sodium level at the time of the neurologic 
deterioration. The acute neurologic deterioration 
may have been precipitated by the administration 
of hypotonic fluids, which further lowered the se-
rum sodium level. We have previously advocated 
the administration of isotonic saline as a prophy-
lactic measure to prevent neurologic complica-
tions from hospital-acquired hyponatremia.5
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in this patient’s neurologic condition. Since this 
is not the diagnostic issue that Dr. Podolsky was 
asked to address in the Clinicopathological Con-
ference, physicians involved in the care of the 
patient provided the following assessment.
Fourteen hours before the seizure, the serum 
sodium level was 131 mmol per liter, and the glu-
cose level was 212 mg per deciliter. After correc-
tion for the elevated glucose level, the effective 
serum sodium level was 133 mmol per liter.1 
Twelve hours before the seizure, the patient vom-
ited several times, and an infusion of half-normal 
saline was begun. Immediately after the seizure, 
the serum sodium level was 127 mmol per liter, 
and the blood glucose level was 492 mg per decili-
ter; the corrected sodium level thus remained 133 
mmol per liter. After the seizure, boluses and an 
infusion of normal saline were administered, and 
the serum sodium level rose to 135 mmol per deci-
liter. During the remainder of the patient’s hospi-
tal stay, the serum sodium level remained between 
127 and 133 mmol per deciliter, despite infusions 
of normal saline and correction of blood glucose 
levels.
The patient’s physicians agree that isotonic 
saline is appropriate fluid replacement for pa-
tients with brain edema. However, this patient’s 
serum sodium level does not appear to have been 
low enough to cause a seizure. Cerebral edema 
attributable to the large B-cell lymphoma of the 
brain likely contributed to the seizure. A syndrome 
of inappropriate antidiuretic hormone secretion 
may have caused persistent mild hyponatremia.
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1,3-β-D-Glucan in Patients Receiving Intravenous 
Amoxicillin–Clavulanic Acid
To the Editor:  The fungal component 1,3-β-D-
glucan is increasingly used to diagnose oppor-
tunistic invasive mycoses in immunocompromised 
patients.1-3 The 1,3-β-D-glucan assay (Fungitell, 
Associates of Cape Cod) was recently approved by 
the Food and Drug Administration. We found that 
the serum samples from two patients with hema-
tologic conditions were positive for 1,3-β-D-glu-
can during treatment with intravenous amoxicil-
lin–clavulanic acid. Serum samples were negative 
after treatment was discontinued. Neither patient 
had evidence of invasive fungal disease. Further-
more, 1,3-β-D-glucan was detected in the amoxi-
cillin–clavulanic acid used to treat these patients. 
We then tested 10 serum samples from six pa-
tients treated with intravenous amoxicillin–clavu-
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lanic acid and found 1,3-β-D-glucan in 9 (cutoff 
value, 60 pg per milliliter). The mean level of re-
activity (1339±1798 pg per milliliter) was signifi-
cantly higher than that in serum samples from 
10 patients treated with ceftazidime (17.7±26.5 pg 
per milliliter, P = 0.002) and from healthy blood 
donors (8.0±13.8 pg per milliliter, P = 0.001). Se-
rum samples from two of the six patients tested 
before the intravenous administration of amoxi-
cillin–clavulanic acid were negative for 1,3-β-D-
glucan, but serum samples taken 20 minutes after 
the end of the infusion were positive (805 and 
446 pg per milliliter).
Ten batches of the amoxicillin–clavulanic acid 
infusion fluid used during this period (including 
the five batches used to treat the six patients) were 
positive for 1,3-β-D-glucan (9414±7774 pg per 
gram of antibiotic), as opposed to four batches of 
ceftazidime infusion fluid (10±21 pg per gram of 
antibiotic, P = 0.004). Both drugs were diluted ac-
cording to standard methods for clinical use, and 
all diluents (i.e., water and 0.9 percent sodium 
chloride) were negative for the glucan. A single 
dose of 1000 mg of amoxicillin plus 200 mg of 
clavulanic acid contained 2856 to 28,016 pg of 
1,3-β-D-glucan, which is 48 to 467 times the cut-
off value in 1 ml of serum.
Serum samples from the six patients treated 
with intravenous amoxicillin–clavulanic acid also 
had significantly higher levels of galactofuranose 
antigens (measured with the use of the Platelia 
Aspergillus enzyme immunoassay, Bio-Rad Lab-
oratories) than the samples from patients treated 
with ceftazidime (P = 0.003) or samples from healthy 
blood donors (P = 0.009). These components are 
used for the diagnosis of invasive aspergillosis4 
and have previously been reported to be present 
in piperacillin–tazobactam and amoxicillin–clav-
ulanic acid.5 In addition, we observed no glucan 
reactivity in five batches of piperacillin–tazobac-
tam (23±26 pg per gram).
These results are highly suggestive of cross-
reactivity of the Fungitell assay with amoxicillin–
clavulanic acid. Physicians should be aware of the 
possibility of false positive 1,3-β-D-glucan results 
in patients treated with this antibacterial agent. 
The presence of two different fungal components 
in the antibiotic provides strong evidence of a 
fungal origin of the cross-reactive components in 
the drugs. Given the difficulties encountered in 
the diagnosis of invasive fungal disease, it would 
be desirable to eliminate the fungal material from 
antibiotic agents.
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Imipenem in Patients with Immediate Hypersensitivity 
to Penicillins
To the Editor: It is considered potentially harm-
ful to administer imipenem–cilastatin to patients 
with IgE-mediated hypersensitivity to penicillins1 
because of a 47.4 percent rate of cross-reactivity 
(9 of 19 subjects) found in a single study2 on the 
basis of positive skin tests involving imipenem 
reagents.
Between 1997 and 2005, we studied 112 con-
secutive patients with such hypersensitivity, di-
agnosed as previously described,3 in order to as-
sess the cross-reactivity with imipenem–cilastatin 
and to evaluate the allergic responses to imipen-
em–cilastatin in patients who had negative skin 
tests. Our patients had had a total of 143 immedi-
ate reactions to penicillins. All patients had posi-
tive skin tests for at least one of the penicillin 
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on July 11, 2012. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
